X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IO-202 is a first-in-class antagonist antibody with specific, high affinity binding to LILRB4. It is being evaluated for the treatment of relapsed or refractory chronic myelomonocytic leukemia.
Lead Product(s): IO-202,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: IO-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Under the collaboration, Roche will conduct clinical trial studies to evaluate the safety, efficacy of IO-108 in combination with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab for the treatment of locally advanced hepatocellular carcinoma.
Lead Product(s): IO-108,Atezolizumab,Bevacizumab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2024
Details:
Proceeds from the financing will be used to accelerate development of Immune-Onc’s lead clinical candidates, IO-108 and IO-202, and advance the selection of additional novel myeloid checkpoint inhibitor programs.
Lead Product(s): IO-108,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Triwise Capital
Deal Size: $131.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 05, 2023
Details:
In hematologic malignancies, preclinical studies showed that IO-202 converts a “don’t kill me” to a “kill me” signal by activating T cell killing and converts a “don’t find me” to a “find me” signal by inhibiting infiltration of blood cancer cells.
Lead Product(s): IO-202,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Details:
IO-108 is a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) in adult patients with advanced or refractory solid tumors.
Lead Product(s): IO-108,Cemiplimab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 17, 2022
Details:
Under the terms of the collaboration, Immune-Onc will sponsor and fund the IO-108 and IO-202 clinical trials in China, and BeiGene will provide tislelizumab. Immune-Onc retains global development and commercial rights to IO-108 and IO-202.
Lead Product(s): IO-108,Tislelizumab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 10, 2022
Details:
IO-106 is third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer.
Lead Product(s): IO-106
Therapeutic Area: Oncology Product Name: IO-106
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2, promotes innate and adaptive anti-cancer immunity in preclinical models, and it is well-tolerated to date in the ongoing Phase 1 study for treatment of solid tumors.
Lead Product(s): IO-108,Pembrolizumab
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
IO-108, a novel antagonist antibody binds to LILRB2 with high affinity and specificity and blocks the interaction of LILRB2 with multiple ligands that are involved in cancer-associated immune suppression for treatment of AML, chronic myelomonocytic leukemia, and solid tumors.
Lead Product(s): IO-108
Therapeutic Area: Oncology Product Name: IO-108
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
IO-202, a first-in-class antibody targeting LILRB4, is in Phase 1 clinical development for the treatment of acute myeloid leukemia and chronic myelomonocytic leukemia.
Lead Product(s): IO-202
Therapeutic Area: Oncology Product Name: IO-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
